Much has been written about the dawn of molecularly targeted cancer therapy. But for people with bowel cancer, progress has been relatively slow compared to other common cancers. And that’s despite the disease’s major molecular pathways being mapped out decades ago.
Thankfully this is starting to change, with a string of recent discoveries revealing profound new insights into bowel cancer biology.
To translate these into new treatment approaches, the £5.5m consortium of international researchers - named CRC-STARS - has recently launched, and is injecting new, and much needed, momentum into the field.
Read the full story on the CRUK website.